Jason LaButti

Jason LaButti has extensive experience in the pharmaceutical industry, spanning over two decades. Jason currently holds the position of Vice President, DMPK at Pretzel Therapeutics, starting in November 2022. Prior to this, they worked at Vesalius Therapeutics as a Senior Director from July 2022 to November 2022.

From November 2021 to July 2022, LaButti served as the Senior Director, DMPK at Ribon Therapeutics. Before that, they worked at Praxis Precision Medicines, Inc. as the Director, DMPK from January 2020 to November 2021.

LaButti's earlier experience includes a significant tenure at Pfizer, where they held the role of Medicine Design Senior Principal Scientist, Rare Disease, Oncology, and Neuroscience from January 2011 to January 2020.

Prior to joining Pfizer, LaButti worked as a Senior Research Chemist at Merck from June 2009 to January 2011 and as a Senior Research Associate at Millennium Pharmaceuticals from May 2000 to May 2005.

Jason LaButti completed their Bachelor's degree in Biochemistry, Biophysics, and Molecular Biology from Rensselaer Polytechnic Institute in 1994. Jason also obtained a Ph.D. in Chemistry from the University of Missouri-Columbia, graduating between 2005 and 2009. Additionally, they hold a Bachelor of Science (B.S.) degree in Biochemistry, Biophysics, and Molecular Biology, though the specific years of completion are not provided.